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Learning and memory impairments occurring with Alzheimer’s disease (AD) are associated with degeneration of the basal
forebrain cholinergic neurons (BFCNs). BFCNs extend their axons to the hippocampus where they bind nerve growth factor
(NGF) which is retrogradely transported to the cell body. While NGF is necessary for BFCN survival and function via binding to
the high-aﬃnity receptor TrkA, its uncleaved precursor, pro-NGF has been proposed to induce neurodegeneration via binding to
the p75NTR and its coreceptor sortilin. Basal forebrain TrkA and NGF are downregulated with aging while pro-NGF is increased.
Given these data, the focus of this paper was to determine a mechanism for how pro-NGF accumulation may induce BFCN
degeneration.Twenty-fourhoursafterasingleinjectionofpro-NGFintohippocampus,wefoundincreasedhippocampalp75NTR
levels, decreased hippocampal TrkA levels, and cholinergic degeneration. The data suggest that the increase in p75NTR with AD
may be mediated by elevated pro-NGF levels as a result of decreased cleavage, and that pro-NGF may be partially responsible for
age-related degenerative changes observed in the basal forebrain. This paper is the ﬁrst in vivo evidence that pro-NGF can aﬀect
BFCNs and may do so by regulating expression of p75NTR neurotrophin receptors.
1.Introduction
Understanding the role of pro-nerve growth factor (pro-
NGF) as an independent ligand is an important part of
determining a mechanism for degeneration of the basal
forebrain cholinergic neurons (BFCNs). BFCNs degenerate
in Alzheimer’s disease (AD) and Down syndrome (DS),
and this phenomenon is believed to explain some of the
cognitive deﬁcits observed in both conditions [1]. In the
United States alone, 5.3 million Americans of all ages have
AD with one in eight people over the age of 65 diagnosed
with AD (Alzheimer’s Association, 2010). The hallmark of
AD is progressive cognitive decline, deﬁned by, but not
limited to: profound memory loss, diﬃculty with planning
andproblemsolving,visuospatialdeﬁcits,anddiﬃcultywith
word use in speaking or writing (Alzheimer’s Association,
2010). Ultimately, the progressive culmination of these
symptoms leadstoaloss ofindependent living.Current drug
therapies for AD target the cholinergic system by increasing
the amount of available acetylcholine without protecting
cholinergic neurons from further degeneration and have
been only mildly successful in slowing the progression
of cognitive impairment in the clinic [2]. Because BFCN
integrity is correlated with cognitive function, it would be
most useful to target the cause of the degeneration rather
than the outcome so that new therapeutics could serve to
reverse or prevent further cholinergic degeneration. Thus, it
is our interest to understand why BFCNs degenerate so that
novel drug targets may be developed to prevent degeneration
and sustain cognition.
Pro-NGF, the 32kD precursor to 14kD mature NGF,
is the predominant form of NGF in the brain [3] and is
elevated in AD [3–5]. Under pathological conditions such
as seizures, pro-NGF is found in astrocytes, [6] and in the
case of inﬂammatory neuropathology, astrocytic IL-1β is
able to regulate NGF secretion [7]. Pro-NGF can be cleaved
intracellularly by furin or proconvertases, or extracellularly
by plasmin (for review see [8]). Brieﬂy, there are essentially2 Journal of Aging Research
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Figure 1: Proposed mechanism of pro-NGF induced neurodegenera-
tioninAlzheimer’sdiseaseandage-matchedcontrols.(1)Thecleavage
of plasminogen to plasmin is altered due to decreased tPA from
increased PAI-1 activity, leading to an accumulation of pro-NGF
in the hippocampus. (2) Increased pro-NGF leads to a preferential
activation of the high aﬃnity p75NTR/sortilin complex. (3) As
NGF is down-regulated and pro-NGF is upregulated, high aﬃnity
NGF binding to TrkA receptors is compromised. (4) There is a
shift in the balance of TrkA and p75NTR at the distal axon of
the BFCN. (5) Pro-NGF/p75NTR/sortilin signaling increases JNK
signalingandultimatelyinducesdegenerationoftheBFCNs.Inage-
matched controls (normal aging), balanced tPA activity allows for
(1) cleavage of pro-NGF to yield NGF and (2) sustained NGF/TrkA
signaling to promote cholinergic integrity. Abbreviations: tissue
plasminogen activator (tPA), plasminogen activator inhibitor-1
(PAI-1), nerve growth factor (NGF), tropomyosin related kinase
A( t r k A= high aﬃnity NGF receptor), pan neurotrophin receptor
p75NTR (p75NTR = high aﬃnity pro-NGF receptor).
two routes for NGF or pro-NGF synthesis. The ﬁrst pathway
resultsinmatureNGFproduction:(1)pro-NGFiscleavedby
plasmintoyieldmatureNGFthatwillbindwithhighaﬃnity
to TrkA receptors on the distal axon in the hippocampus,
followed by retrograde transport in signaling endosomes to
the cell body in the basal forebrain. This pathway promotes
survival of the BFCNs via PI3/Akt signaling. The second
signaling pathway results in the production of un-cleaved
pro-NGF; (2) pro-NGF in its native state binds with high
aﬃnity to p75 receptors (p75NTR) and the co-receptor
sortilin to induce cell death via the JNK pathway [9]. These
two separate pathways contribute to BFCN cell survival or
cell degeneration, respectively (see Figure 1).
Pro-NGF is the predominant form of NGF throughout
adulthood [3], but in mouse models of AD [10]a n dh u m a n
AD [5, 11], pro-NGF is signiﬁcantly elevated compared
to age-matched controls in the hippocampus and frontal
cortex and entorhinal cortex, respectively [10, 11]. In a
mousemodelofDS,whichdisplaysthesameneuropathology
as AD, retrograde transport of the TrkA/NGF signaling
endosomes is disrupted which leads to a decrease in NGF
for the BFCNs [12]. The decrease in basal forebrain (BF)
N G Fc o i n c i d e sw i t had e c r e a s ei nB FT r k Ar e c e p t o r s[ 13–
15] while p75NTR expression remains unchanged in the BF
[4]. Research from our group in aged rats has demonstrated
that lack of access to NGF in BFCNs is not due to reduced
release of NGF from hippocampal neurons [16]; instead, the
ﬁndings suggested a lack of ERK-mediated cell signaling in
the septohippocampal pathway giving rise to increased levels
ofNGFinthehippocampus,ononehand,andreducedlevels
in the basal forebrain, on the other hand [17]. The inability
to respond to injected exogenous NGF correlated strongly
with performance on a spatial memory task, suggesting
that the NGF signaling pathways were directly involved in
performance in these working memory tasks [17]. Even
though these ﬁndings point to altered downstream NGF
problems with aging and in AD, recent ﬁndings suggest that
upstreamcleavagemechanismsforpro-NGFarealsoaﬀected
by aging and disease processes.
Upstream events include the metabolic events regulating
pro-NGF expression. One key component of pro-NGF
regulation is the plasminogen cascade (see Figure 1), which
ultimately yields plasmin to convert pro-NGF to NGF. In
human AD, activity of tissue plasminogen activator (tPA) is
reduced as well as plasminogen and plasmin levels [10, 18],
leaving pro-NGF unable to be converted to mature NGF.
Similarly, in mouse models of AD, tPA levels are decreased
[19] and the tPA inhibitor, PAI-1 is increased [20]. Current
evidence in the ﬁeld strongly suggests that these conditions
favor accumulation of pro-NGF in AD [3, 4, 11].
Consequences of increased pro-NGF may be numerous,
but at least one consequence supported by our data and
others, is a compromise of TrkA signaling or expression.
Using PC12 cells, Sobottka et al. [21]p r o v i d e de v i d e n c et h a t
wildtype pro-NGF, when coincubated with NGF, decreased
TrkA mediated MAPK activation due to pro-NGF outcom-
peting mature NGF. Additionally, it was recently shown that
pro-NGF can suppress PI3K to inhibit TrkA signaling via
PTEN in basal forebrain neurons in vitro [22]. Finally, Al-
Shawietal.[4]usedsuperiorcervicalgangliaculturesinvitro
and basal forebrain slices ex vivo, both of which responded
with increased cell death when treated with pro-NGF, but
these diﬀerences were not attributed to TrkA expression.
While more evidence continues to implicate pro-NGF in
cholinergic degeneration, causal studies understanding the
sequence of events upstream and its consequences down-
stream in vivo have not been well developed. In an eﬀort to
understand BFCN degeneration, it is necessary to consider
not only the ratio of pro-NGF to mature NGF but also the
ratio of the high aﬃnity receptors (p75NTR and TrkA, resp.)
present at the distal axon that are communicating to the
cholinergic cell body in the BF.
In line with studies conducted by Song et al. [22], we
hypothesizethatpro-NGFaccumulationcausesasubsequent
decrease in TrkA signaling through preferential activation
of the p75NTR receptor in vivo. Our ﬁnding that p75NTR
receptor upregulation follows pro-NGF accumulation while
simultaneously decreasing TrkA is an important ﬁnding to
suggest that the receptor imbalance is a consequence ofJournal of Aging Research 3
neurotrophin expression. Therefore, this is the ﬁrst study to
demonstrate that pro-NGF may directly relate to cholinergic
degeneration in an intact animal.
2.ExperimentalProcedures
2.1. Animals. Fifteen male Fischer 344 rats were used: N = 9
aged (20 months of age) and N = 5 young (6 months of
age). One aged saline animal was lost due to the presence
of a pituitary tumor. In an additional control study, three
aged rats were used to determine possible toxicity of pro-
NGF in vivo. Rats were fed food and water ad libitum and
housed on a 12:12 hour light cycle. All animal procedures
were approved by the Institutional Animal Care and Use
Committee at the Medical University of South Carolina and
adhered to NIH guidelines.
2.2. Surgical Procedure. Young and aged rats were divided
into three groups (n = 4-5 each): aged controls (20 months
ofage),youngcontrols(6monthsofage),andagedpro-NGF
injected (20 months of age) rats. Under ketamine/xylazine
anesthesia, all animals received bilateral hippocampal injec-
tions at coordinates targeted for dorsal hippocampus: AP-
5.30, ML ± 4.5, DV-4.0 (modiﬁed from Williams et al.
[23]). Animals received either saline (10μL/hemisphere) or
pro-NGF intracranial injections (5μgi n1 0μL/hemisphere;
Scil Proteins, Halle, Germany). Saline or pro-NGF was
delivered at a rate of 1μL/minute over 10 minutes with a 5-
minute wait period before and after injection. After surgery,
rats were allowed to recover under careful supervision
until normal locomotor activity returned. All animals were
sacriﬁced 24 hours after injection by isoﬂurane overdose
followed by decapitation, at which time the hippocampus
and medial septal area of basal forebrain were dissected
bilaterally with a dissecting microscope, placed on ice, ﬂash
frozen in separate tubes, and stored at −80◦C until Western
blot analyses. Brains collected from the toxicity study were
used for immunohistochemistry and were placed in 4%
paraformaldehyde in 0.1M phosphate buﬀer (PB) for 48hrs,
and transferred to 30% sucrose in 0.1M PB for a minimum
of 48hrs before being sectioned on a cryostat at 20μm.
2.3. Veriﬁcation of Injection Site. Preliminary studies were
conducted in order to test the toxicity and/or physiolog-
ical eﬀects of pro-NGF injections into aged rats while
simultaneously determining the success rate for bilateral
injections into hippocampus. To this end, 6 animals were
given either pro-NGF (n = 4) or saline (n = 2) and
sacriﬁced 24 hours later to visualize injection sites within
the hippocampus and examine ChAT immunostaining (see
Section 2.6). Injection sites were veriﬁed with Cresyl violet
staining (see Supplementary Figure 2 in supplementary
Material available online at doi: 10.4061/2011/460543.).
2.4. Sample Preparation. The basal forebrain containing
the medial septal area and bilateral hippocampi containing
the injection site were microdissected, weighed, then snap
frozen on dry ice. Before beginning the total protein
bicinchoninic acid (BCA) assay (Pierce, Rockford, IL), all
tissues were diluted 1:10w/v in lysis buﬀer (in dH20: 1%
NP40, 150.5mM NaCl, 3.5mM SDS, 5% Tris Base, pH
7.4) containing protease (Calbiochem, Los Angeles, CA) and
phosphatase inhibitors (Roche, Indianapolis, IN), followed
by approximately 15 triturations with a 20-gauge needle,
stored on ice for 60 minutes, then centrifuged at 14000rpm
for 20mins. After homogenization, the BCA assay was
performed on the supernatant. The pellet and aliquots of the
remaining supernatant were stored at −80◦C for later use.
2.5. Western Blotting. Samples (20μg for all blots except pro-
NGF which required 75μg) were loaded in duplicate and
separated on 4–12% Bis Tris gels (Invitrogen, Carlsbad, CA)
at 150V for 45 minutes. After separation onto the gel, the
gel was transferred via wet transfer onto a nitrocellulose
membrane for one hour at 30V. The membrane was then
removed from the cassette and blocked for one hour in 5%
nonfat milk in PBS-T (0.1% Tween-20) at room temperature
and subsequently incubated overnight at room temperature
in primary antibody. The following day blots were washed in
PBS-T then incubated in secondary antibody in 5% nonfat
milk in PBS-T for one hour at room temperature. Blots
were then washed in PBS-T then imaged on a Kodak Image
Station 4000 (4 exposures, 15sec each) using Immobilon
chemiluminescent reagent (Millipore, Bellerica, MA). For
loading control, blots were incubated with mouse antiactin
antibody for one hour at room temperature, then incubated
in secondary antibody, then ﬁnally reimaged under the same
settings. Primary antibodies used include rabbit anti-TrkA
(1:1000, kindly provided by Dr. Louis Reichardt), mouse
anti-β-Actin (1:10,000, Sigma, St. Louis, MO), mouse anti-
p75NTR (1:1000, Millipore, Bellerica, MA), rabbit anti-
caspase-3 (1:1,000, Stressgen, Ann Arbor, MI), rabbit anti-
sortilin (1:1000, Abcam, Cambridge, MA), rabbit antiplas-
minogen (1:500, R&D Systems Inc., Minneapolis, MN),
rabbit anti-Pro:NGF (1:200, Alomone Labs, Jerusalem,
Israel) and secondary antibodies include donkey anti-rabbit
HRP (1:5000, Jackson Immunoresearch, West Grove, PA),
donkey antimouse HRP (1:5000, Jackson Immunoresearch,
West Grove, PA). Rabbit anti-Pro-NGF blocking peptide
was prepared in equal concentration to primary antibody
and was incubated overnight at 4◦Ci n5 %m i l ki nP B S -
T before use on membrane. Densitometry was performed
using Fluorchem software (Alpha Innotech, San Leandro,
CA); samples were normalized to protein standards on each
blot then normalized to actin. Results are therefore reported
as relative density.
2.6. ChAT Immunohistochemistry. Rats used to verify hip-
pocampal injection sites were also used for ChAT immuno-
histochemistry; these brain sections also allowed us to
preliminarily determine if pro-NGF would have a direct
eﬀect on BFCN morphology. To that end, brains were
sectioned at 20μm and every third section was collected for
immunohistochemical analyses for a total of approximately
10 sections per brain area. Sections were mounted onto
slides pretreated with etching solution for 10 minutes (70%
TBS, 20% Methanol, 10% H202), then washed and blocked
in 10% NDS in TBS-Triton for one hour. Slides were4 Journal of Aging Research
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Figure 2: Intra-hippocampal injections of pro-NGF signiﬁcantly increased hippocampal expression of pro-NGF (a), but did not alter basal
forebrain pro-NGF levels (b). The pro-NGF antibody was speciﬁc for pro-NGF (∼32kD) and did not detect mature NGF protein levels as
shown in a pro-NGF treated animal; when incubated with pro-NGF blocking peptide, no bands were present (c). Changes in protein levels
were normalized to β-Actin; ∗P ≤ .05.
then incubated with rabbit anti-ChAT (1:500, Chemicon,
Billerica, MA) overnight followed by donkey anti-rabbit
secondary (1:200, Jackson Immunoresearch, West Grove,
PA) for one hour. Finally, slides were incubated in ABC
solution (Vector, Burlingame, CA) and developed with
3,3 -diaminobenzidine tetrahydrochloride (DAB, Sigma, St.
Louis, MO). The slides were cover-slipped with Permount
(Fisher Scientiﬁc, Fair Lawn, NJ) and allowed to dry.
2.7. Statistical Analyses. For each brain area (basal forebrain
and hippocampus) and each marker, when all three groups
were compared, a oneway ANOVA was used to assess for
potential group diﬀerences, then Fischer’s PLSD post hoc
analyses were used to compare individual groups when
group eﬀects were present. In all cases, we were interested
in comparing the young versus aged saline groups and the
aged saline versus aged pro-NGF group. All statistics were
performed using Statview version 5.0 (Abacus Corporation,
Baltimore, MD), with a P ≤ .05 considered signiﬁcant.
3. Results
3.1. Hippocampal and Basal Forebrain Levels of Pro-NGF.
Intrahippocampal injections of pro-NGF produced a signif-
icant upregulation of pro-NGF protein in the hippocampus
(Figure 2(a), F2,11 = 5.597, P = .0211). Pro-NGF injected
rats had signiﬁcantly more pro-NGF than aged saline
injected rats (P = .05) and young saline injected rats
(P = .0074) as indicated by Fisher’s post-hoc analyses.
Qualitatively, aged saline rats appeared to have more pro-
NGF protein than young saline rats; however, this was not
statistically signiﬁcant (P = .3664). In the basal forebrain
intra-hippocampal injections of pro-NGF had no eﬀect on
pro-NGF expression (Figure 2(b), F2,11 = 0.462, P = .6415),
mostlikelysuggestingthatpro-NGFisnottransportedtothe
BFCN via retrograde transport.
3.2. Hippocampal and Basal Forebrain Levels of p75NTR
Receptors. After Intrahippocampal injection of pro-NGF,
there was a signiﬁcant eﬀect of treatment on hippocampal
p75NTR receptor levels using Western blots (Figure 3(a),
F2,11 = 8.374, P = .0062). Following Fisher’s post-hoc
analyses, aged rats exhibited signiﬁcantly higher p75NTR
receptor protein levels in the hippocampus than young
rats when comparing the two saline injected groups (P =
.0427). In addition, aged rats treated with pro-NGF had
signiﬁcantly greater p75NTR protein expression than aged
saline-injected rats, suggesting that pro-NGF administration
further aggravated age-related alterations in hippocampal
p75NTR levels (P = .0395). The observed increase in
p75NTR levels in the hippocampus following pro-NGF
injections was not replicated in the basal forebrain, even
though an overall ANOVA revealed a main eﬀect of group
in the basal forebrain for p75NTR levels (Figure 3(b), F2,11 =
5.763, P = .0194). The main eﬀect in the basal forebrain was
largely due to an increase in p75NTR receptor levels in the
aged saline group compared to the young saline group (P =
.0084), rather than resulting from the pro-NGF treatment.Journal of Aging Research 5
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Figure 3: Aging resulted in an increase of p75NTR in the hippocampus (a) and basal forebrain (b), but only in the hippocampus was
pro-NGF capable of signiﬁcantly increasing p75NTR (a). Pro-NGF treatment decreased total hippocampal trkA (c) but did not signiﬁcantly
decrease total basal forebrain TrkA (d). Sortilin levels were not altered in the hippocampus (e) or basal forebrain (f). Changes in protein
levels were normalized to β-Actin; ∗P ≤ .05.6 Journal of Aging Research
(a) (b) (c)
Figure 4: Pro-NGF treatment resulted in observable degeneration of the cholinergic neurons stained for Choline Acetyl Transferase (ChAT;
(b), (c)) when compared to age matched saline animals (a). Arrows in (b) point to neurons represented in (c) under higher magniﬁcation.
Scale bar = 50μm, 20x ((a) and (b)) and 40x (c).
3.3. Hippocampal and Basal Forebrain Levels of TrkA Recep-
tors. In the hippocampus, total TrkA protein was signif-
icantly diﬀerent across experimental groups (Figure 3(c),
F2,11 = 4.481, P = .0377). This diﬀerence was due
to aged pro-NGF rats having signiﬁcantly less total TrkA
protein compared to young (P = .0192) and aged saline
rats (P = .0383). In an attempt to determine the cause
of reduced total TrkA protein from pro-NGF treatment,
the 110kD and 140kD forms of the TrkA receptor were
individually analyzed. Because previous work has shown
diﬀerences in NGF sensitivity for these two forms [24], we
used western blotting to identify and quantify both forms.
Intracellular, nonglycosylated 110kD TrkA was signiﬁcantly
r e d u c e di no n l yp r o - N G Ft r e a t e dr a t s( F2,11 = 5.867, P =
.0184, Supplementary Figure 1C) but 140kD TrkA levels
were unaﬀected (F2,11 = .220, P = .8058, Supplementary
Figure 1B). This was examined further by calculating the
ratio of 140kD versus 110kD TrkA, where there was a
main eﬀect of group (F2,11 = 6.886, P = .0115; Supple-
mentary Figure 1A), and Fisher’s post-hoc analysis revealed
that the diﬀerences were speciﬁcally due to the pro-NGF
treated rats having signiﬁcantly lower levels of the precursor
(110kD) TrkA form, compared to mature TrkA (140kD)
relative to both the aged (P = .0382) and young saline-
treated rats (P = .0039).
Total TrkA was not signiﬁcantly diﬀerent between groups
in the basal forebrain (Figure 3(d), F2,11 = .111, P = .8962).
There was no diﬀerence between the groups for either the
110kD (F2,11 = .008, P = .9918, Supplementary Figure 1H)
or the 140kD TrkA levels (F2,11 = 2.673, P = .1132, Supp-
lementary Figure 1G) using a one-way ANOVA. Similar to
the TrkA levels in the hippocampus described above, there
was a signiﬁcant diﬀerence in the ratio of 140kD to 110kD
TrkA form in the basal forebrain across all groups (Sup-
plementary Figure 1F, F2,11 = 4.143, P = .045). However,
contrary to ﬁndings in the hippocampus, Fisher’s post-
hoc analysis demonstrated that basal forebrain levels were
signiﬁcantly diﬀerent between the young and the aged saline
group (P = .025) but not between the aged saline and pro-
NGF groups (P = .0959), suggesting that TrkA levels in basal
forebrain were not aﬀected by pro-NGF treatment, at least at
the 24-h postinjection time point examined here.
3.4. Hippocampal and Basal Forebrain Levels of Sortilin.
Sortilin interacts with p75NTR to bind pro-NGF and
induce cell death signaling [24]. In the hippocampus, total
sortilin protein did not signiﬁcantly diﬀer between groups
(Figure 3(e), F2,11 = .004, P = .9957). Total sortilin protein
expression in the basal forebrain also did not diﬀer between
groups (Figure 3(f), F2,11 = 1.641, P = .2378), but an
independent sample t-test revealed a trend for signiﬁcantly
less sortilin in the young saline group compared to the
aged saline group (P = .0989). This suggests that pro-NGF
treatment did not aﬀect sortilin total protein expression in
either the hippocampus or the basal forebrain.
3.5. BFCN Atrophy as a Result of Pro-NGF Injection. The
eﬀects of a single intrahippocampal injection of pro-NGF
upon the morphology of BFCN neurons were examined
using immunohistochemistry with an antibody directed
against ChAT. Morphological assessment of sections from
the pro-NGF treated group revealed cell body atrophy as
well as reduced ChAT immunoreactivity within each neuron
(Figure 4(b)) when compared to age matched saline-treated
rats (Figure 4(a)). In addition, fewer neurites in the vicinity
of cell bodies, as well as enlarged nuclei were observed
following the pro-NGF injection (Figure 4(b)), indicative of
a decrease in cholinergic integrity. Importantly, these are the
ﬁrst studies examining eﬀects of pro-NGF injections in vivo
in aged rats, demonstrating that pro-NGF may compromise
cholinergic neuron integrity through a p75NTR-dependent
mechanism.
4. Discussion
Pro-NGF is elevated in the hippocampus in AD and may
be result in an altered TrkA/p75 ratio as well as BFCN
degeneration. In an attempt to model the elevated pro-
NGF levels observed in patients with AD, we injected
pro-NGF into the hippocampus of aged rats. We report
that injecting pro-NGF directly into the hippocampus of
aged rats signiﬁcantly increased p75NTR receptor expression
while decreasing total TrkA receptor protein. Until now, the
role of pro-NGF levels for TrkA/p75NTR expression had
not been examined in vivo. Our data conﬁrm and extend
previous in vitro studies [22] that suggest that p75NTRJournal of Aging Research 7
receptor activation can down-regulate TrkA expression,
except our ﬁndings are in the intact animal. We also have
preliminary data to suggest that injection of pro-NGF into
the hippocampus aﬀects cholinergic neuron morphology
in the basal forebrain, previously only shown in vitro
[4, 9]. Understanding the precise modulation of the NGF
trophic factor system in the AD disease process is essential
for developing novel drug compounds that could rescue
cholinergic degeneration and enhance cognition in AD.
Combined, the present data strongly suggest that elevation
of pro-NGF levels, at least in the aged brain, leads to a switch
from TrkA to p75NTR expression and that such a receptor
switch may have implications for cholinergic degeneration.
4.1. Alterations in Pro-NGF Levels. Pro-NGF is the predom-
inant form of NGF in the brain [3] and is elevated in AD
[3, 4, 11]. In the present study, aged rats were injected with
pro-NGF to determine in vivo eﬀects of these injections on
the TrkA/p75NTR receptor expression and on cholinergic
degeneration. There was a slight increase in pro-NGF with
aging alone, but when aged animals were injected with
pro-NGF, there was signiﬁcantly more pro-NGF protein
expressed in the hippocampus but not in the basal forebrain,
suggesting that the injected pro-NGF was not transported
via retrograde transport to the BFCN. We also observed that
there was not a signiﬁcant increase in pro-NGF with aging
alone in the basal forebrain. While the lack of increased pro-
NGF in injected rats was not a surprise, we expected that
pro-NGF levels would be increased with normal aging based
on the evidence for increased pro-NGF in the hippocampus
[3,4],decreasedmatureNGFinthebasalforebrain[12],and
evidencethatpro-NGFappliedtothebasalforebraindirectly
is capable of inducing neurodegeneration [4, 9]. We believe
that the failure to see any changes in the basal forebrain does
not imply that the ratio of pro-NGF to mature NGF at the
distal axon is irrelevant but instead warrants further investi-
gation as our studies were performed in the intact animal.
4.2. Alterations in p75NTR Levels. Interactions with the
p75NTR neurotrophin receptor have been implicated in
synapse elimination [25], cell death following seizures [22],
and retinal degeneration [26]. However, evidence regarding
altered p75NTR receptor levels in the basal forebrain with
aging or disease has been controversial. Mufson et al. [27]
reported that there is a loss of basal forebrain/medial septal
p75NTR positive neurons in humans with AD, while Al-
Shawi et al. [4] reported no change in p75NTR-positive cells
in aged mice by using mean gray value density analyses. By
analyzing tissue homogenates from speciﬁc brain regions,
we found a signiﬁcant increase in p75NTR levels in both
the basal forebrain and the hippocampus in the aged rat
in the current study. Interestingly, treatment with pro-NGF
exacerbated the p75NTR upregulation in the hippocampus,
but not in the basal forebrain. This ﬁnding could be a
result of the p75NTR remaining at the location of the
distal axon in the hippocampus so that it may then be
shed and recycled for reinsertion without ever being fully
transported back to the basal forebrain. Further studies are
necessary to investigate this potential phenomenon. The
changes in p75NTR expression as a result of aging alone may
be explained by a long term, chronic process that may be
regulated by inherent pro-NGF production. Future studies
willneedtodeterminethemembraneboundversuscytosolic
p75NTR expression at various time points in order to fully
appreciate the role that p75NTR may have in dictating the
pro-NGF response.
4.3. TrkA Expression in the Hippocampus. Expression of the
TrkA receptor in the hippocampus is a controversial topic.
While we acknowledge that the majority of the TrkA in
the septohippocampal pathway is expressed in the basal
forebrain, TrkA is also present in cholinergic neurites within
the hippocampus, and it is clear from a multitude of studies
that the TrkA protein [28–30], while produced in the BFCN,
is transported via axonal transport to the terminal ﬁeld in
the hippocampus, where it exerts the majority of its eﬀects
at the synaptic cleft following activity-dependent release
of NGF from the postsynaptic hippocampal neuron. TrkA
receptors are also highly expressed on the cell body surface
in the basal forebrain, and we suggest that these receptors
may be produced locally from mRNA in the cell body,
or regulated by the TrkA/NGF signal from the distal axon
via signaling pathways. In summary, the presence of TrkA
in the hippocampus (on the axon terminal) may play an
essential role in regulating the interaction with p75NTR that
may convey the death/survival signal to the basal forebrain
cholinergic neurons.
We hypothesize that increased pro-NGF binding to the
P75 receptor may lead to a subsequent disruption in the
maturation process of the functional TrkA receptor. This
is illustrated by signiﬁcantly lower levels of the nonglyco-
sylated 110kD precursor form of the TrkA protein in the
hippocampus of pro-NGF treated rats compared to either
young saline or aged saline-treated rats and a trend for
decreased mature 140kD hippocampal TrkA in pro-NGF
treated rats. An earlier time point may have been necessary
to capture a more absolute eﬀect of pro-NGF treatment on
TrkA because we previously demonstrated an upregulation
of TrkA as early as 15 minutes after exogenous NGF injection
into the hippocampus [17]. Also, TrkA has a short half
life of approximately 138 minutes [24], and any signiﬁcant
changes that may have occurred would be missed by a 24-
hour time point. Future studies will be conducted involving
the administration of pro-NGF with an immediate and long-
term time course to further characterize the timeline for the
TrkA:p75NTR shift observed herein.
4.4. TrkA Expression in the Basal Forebrain. Previous work
from our group and others has shown reduced basal
forebrain TrkA with aging [12, 17, 27]. Results in the current
study only reﬂect a trend for an age-related decrease in TrkA
that is likely due to low sample size. It is interesting, however,
that pro-NGF injections did not aﬀect the basal forebrain in
the same way as the hippocampus was aﬀected. This may be
due to a time-dependent process whereby ﬁrst the TrkA is
downregulated at the distal axon (which we observed at 24
hours), followed by decreased TrkA mRNA and protein in
the cell body in the basal forebrain. It is also possible that8 Journal of Aging Research
increased p75NTR signaling may suppress the anterograde
transport of TrkA receptors to the distal axon to bind to
(decreased) NGF as an early process in p75NTR suppression
of TrkA signaling. We have previously demonstrated that
administration of mature NGF can rapidly and signiﬁcantly
increase the expression level of TrkA receptors in the aged
rat [17, 31], showing a direct relationship between access
to the growth factor and expression of its high-aﬃnity
receptor. Elevated pro-NGF levels would therefore function
in the same manner, limiting the access of mature NGF to
cholinergic neurites in the hippocampus.
4.5. Alterations in Sortilin. Sortilin interacts with p75NTR to
bind pro-NGF at the distal axon of the BFCNs which then
promotes cell death signaling to the BFCNs [32]. In both
the hippocampus and the basal forebrain, sortilin levels were
unchanged. However, in the basal forebrain, we found that
there was a trend for increased sortilin with aging, which
has been observed by others [4, 33]. We hypothesized that
an increase in p75NTR expression with pro-NGF treatment
and aging would be associated with an increase in sortilin
because sortilin is required for p75NTR interactions with
pro-NGF [32]. However, our lack of ﬁndings are interesting
considering that sortilin is also essential for anterograde
transport of TrkA receptors [34], which would suggest that
sortilin levels may be unchanged because of the ubiquitous
presence of sortilin in the CNS, and suggests distribution
rather than overall level changes.
4.6. Alterations in Plasminogen. The plasminogen cascade
has gained much attention due to its role in proteolytic
cleavage processes. Plasminogen is converted to plasmin by
the enzyme tissue plasminogen activator (tPA), and plasmin
cleaves pro-NGF to mature NGF where tPA is regulated by
plasminogen activator inhibitor-1 (PAI-1). One mechanism
that may explain BFCN degeneration in AD is that the
processing enzymes for the conversion of pro-NGF to NGF
are disrupted; therefore, we explored plasminogen levels as
a result of aging and pro-NGF treatment. Individuals with
AD have decreased plasmin [18] and tissue plasminogen
activator (tPA) activity [19]. Additionally, the inhibitor of
tPA, PAI-1, is elevated in AD [19]. All of these processes may
lead to increased pro-NGF expression. Our results replicate
the idea of decreased plasminogen in the presence of excess
pro-NGF, suggesting a disruption in the proteolytic cleavage
process of pro-NGF.
4.7. Eﬀects of Pro-NGF on Cell Morphology. We also observed
qualitative changes in ChAT staining after pro-NGF treat-
ment in the basal forebrain; pro-NGF treatment resulted
in atrophy of cell bodies and retraction of neurites which
we believe represents the early stages of degeneration. This
decrease in cholinergic integrity parallels the increase in
pro-NGF protein (see Figure 2). Cleaved caspase-3 levels
are increased in basal forebrain cultures after treatment
with pro-NGF and are associated with decreased neuronal
survival [9]. In an attempt to replicate these ﬁndings in vivo
and explore a mechanism by which the pro-NGF treatment
could result in p75NTR upregulation, trkA downregulation
and cholinergic compromise, we examined caspase-3 levels
(Supplementary Figure 1). We found no diﬀerence in either
cleaved or uncleaved caspase-3 protein in either the hip-
pocampus or basal forebrain. While we were hopeful to
replicate these ﬁndings, we believe our lack of results may be
due to the prolonged timepoint used in our study compared
to the acute timepoint of 45 minutes used by Volosin et al.
[9]o rm a ya l s ob ed u et od i ﬀerences in in vitro versus in vivo
conditions.
4.8. Comments Regarding a Possible Mechanism. Until this
report,therehavebeennostudiesregardingtheinvivoeﬀects
of pro-NGF treatment. These experiments are essential to
understanding how upstream proteolytic cleavage of pro-
NGF may aﬀect the TrkA/p75NTR ratio known to play
an important role in BFCN survival and function. It is
understood that (1) retrograde signaling mechanisms of
NGF are disrupted in AD, (2) proteolytic processing is
disrupted in AD, and (3) pro-NGF interacts with p75NTR
and sortilin. However, the sequence of events is only starting
to be developed. This study provides the ﬁrst insight to how
increasingpro-NGFlevelsmayalterorfurtherexacerbatethe
TrkA/p75NTR balance in the aged rat. We hypothesize that
upstream mechanisms (plasminogen cleavage to plasmin)
regulating pro-NGF cleavage are altered ﬁrst, followed by a
shift in the TrkA/p75NTR balance in the distal axon that
leadstoadown-regulationinretrogradeNGF/TrkAsignaling
and an increase in p75NTR/sortilin/pro-NGF signaling. This
is illustrated in Figure 1. Future studies will aim to further
characterize the time course, the sequence of events, and
signaling pathways involved in pro-NGF induced BFCN
degeneration.
4.9. Conclusion. In conclusion, this is the ﬁrst report to
demonstrate that pro-NGF administration into the hip-
pocampus in the aged rat gives rise to an increase in p75NTR
signaling while subsequently decreasing TrkA signaling.
We propose that this altered TrkA/p75NTR balance leads
to BFCN degeneration that is associated with cognitive
impairment in AD [1]. These important ﬁndings serve as
a guide for future work related to novel drug design in the
ﬁeld of age-related cholinergic degeneration and memory
loss with Alzheimer’s disease.
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